

Statement of Unaudited Consolidated Results for the Quarter ended 30 June 2015

(₹ in Lacs) Notes:

Sr. No.	Particulars	Quarter Ended		Year Ended	
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2015	2015	2014	2015
PART I					
1	Income from operations				
	a) Net sales/Income from operations (Net of excise duty)	143838	152325	146053	577614
	b) Other operating income	2017	1329	1260	5011
	Total income from operations (net)	145855	153654	147313	582625
2	Expenses				
	a) Cost of materials consumed	52512	50926	58687	223601
	b) Purchase of stock-in-trade	3957	8814	9388	29405
	c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(1886)	11628	3849	13164
	d) Power and fuel expense	10212	9515	9892	39304
	e) Employee benefits expense	27421	27512	27222	109028
	f) Depreciation and amortization expense	7021	6621	7305	28795
	g) Other expenses	20697	20515	23724	99197
	Total expenses	119934	135531	140067	542494
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	25921	18123	7246	40131
4	Other income	380	583	415	4245
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	26301	18706	7661	44376
6	Finance costs (Refer note 4 below)	9640	8540	7789	35534
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	16661	10166	(128)	8842
8	Exceptional items (Refer note 5 below)	(194)	3387	1867	4810
9	Profit/(Loss) from ordinary activities before tax (7-8)	16855	6779	(1995)	4032
10	Tax expense (Net)	4049	2506	(2933)	8048
11	Net Profit/(Loss) from ordinary activities after tax (9-10)	12806	4273	938	(4016)
12	Extraordinary items (net of tax expenses)	-	-	-	-
13	Net Profit/(Loss) for the period (11-12)	12806	4273	938	(4016)
14	Share of Profit/(Loss) of associates	-	-	-	-
15	Minority Interest	-	-	460	1760
16	Net Profit/(Loss) after taxes, minority interest and share of profit/loss of associates (13-14-15)	12806	4273	478	(5776)
17	Paid-up equity share capital (Face value per share ₹ 1)	1593	1593	1593	1593
18	Reserves (excluding revaluation reserve)				243759
19	Earnings per share of ₹ 1 each before and after extraordinary items (Not annualized)				
	Basic (₹)	8.04	2.68	0.30	(3.63)
	Diluted (₹)	8.04	2.68	0.30	(3.63)
PART II					
A PARTICULARS OF SHAREHOLDING					
1	Public shareholding				
	- Number of shares (₹ 1 each)	73230083	73230083	73230083	73230083
	- Percentage of shareholding	45.98	45.98	45.98	45.98
2	Promoters and promoter group shareholding				
	a) Pledged/Encumbered				
	- Number of shares (₹ 1 each)	11137000	11137000	9700000	11137000
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	12.94	12.94	11.27	12.94
	- Percentage of shares (as a % of the total share capital of the Company)	6.99	6.99	6.09	6.99
	b) Non-Encumbered				
	- Number of shares (₹ 1 each)	74914056	74914056	76351056	74914056
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	87.06	87.06	88.73	87.06
	- Percentage of shares (as a % of the total share capital of the Company)	47.03	47.03	47.93	47.03
B Investor Complaints					
	Pending at the beginning of the quarter	Nil			
	Received during the quarter	1			
	Disposed off during the quarter	Nil			
	Remaining unresolved at the end of the quarter	1			

1. Unaudited Consolidated Segment wise Revenue, Results and Capital Employed for the Quarter ended 30 June 2015

Sr. No.	Particulars	Quarter Ended		Year Ended	
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2015	2015	2014	2015
1	Segment revenue				
	a) Pharmaceuticals	74088	76256	60417	268204
	b) Life Sciences Ingredients	71863	77554	86988	314970
	Total	145951	153810	147405	583174
	Less : Inter segment revenue	96	156	92	549
	Net Sales/Income from operations	145855	153654	147313	582625
	a) Pharmaceuticals	74088	76256	60417	268204
	b) Life Sciences Ingredients	71767	77398	86896	314421
	Total	145855	153654	147313	582625
2	Segment results (profit+/-)/loss(-) before tax, exceptional items and interest from each segment				
	a) Pharmaceuticals	17778	15819	(1371)	25138
	b) Life Sciences Ingredients	10010	4377	11121	23393
	Total	27788	20196	9750	48531
	Less : i. Interest (Finance costs)	9640	8540	7789	35534
	ii. Exceptional items and un-allocable expenditure	1698	5397	4371	13032
	iii. Exceptional items and un-allocable income	(405)	(520)	(415)	(4067)
	Total Profit/(Loss) before tax	16855	6779	(1995)	4032
3	Capital Employed (Segment assets less Segment liabilities)				
	a) Pharmaceuticals	514244	496915	499131	496915
	b) Life Sciences Ingredients	210826	194997	237060	194997
	Total capital employed in segments	725070	691912	736191	691912
	Add: Un-allocable corporate assets less liabilities (excluding deferred tax liabilities)	42885	56554	39360	56554
	Total capital employed	767955	748466	775551	748466

2. The unaudited consolidated results of Jubilant Life Sciences Limited ("the Company") and its subsidiaries (collectively known as "the Group") are prepared in accordance with principles and procedures for the preparation and presentation of consolidated accounts as set out in Accounting Standard (AS) 21 "Consolidated Financial Statements" specified under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014.

3. The Company has opted to publish Consolidated Financials Results for Financial Year 2016. The Standalone Financial Results are available at Company's website, www.jubl.com and on the website of the Stock Exchanges, www.bseindia.com and www.nseindia.com. Key Standalone Financial Information of the Company is as under:

(₹ in Lacs)

Particulars	Quarter Ended		Year Ended	
	30 June	31 March	30 June	31 March
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	2015	2015	2014	2015
Total income from operations (net)	66913	72426	103624	317630
Profit/(loss) before tax (after exceptional items)	1304	(22091)	19077	24630
Net profit/(loss) after tax (after exceptional items)	740	(20689)	20372	20511

Above figures for the current period are not comparable to the previous periods due to transfer of certain businesses to Jubilant Generics Limited, a step-down wholly owned subsidiary with effect from 1 July 2014.

4. Finance costs include :

i) Exchange difference arising from foreign currency short-term borrowings regarded as an adjustment to interest costs as per Accounting Standard (AS) 16 "Borrowing Costs", and is gross of credit on the swap contracts as under:

(₹ in Lacs)

Particulars	Quarter Ended		Year Ended	
	30 June	31 March	30 June	31 March
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	2015	2015	2014	2015
Finance costs net of credit on swap contracts	9265	7920	6341	30272
Add: foreign exchange differences and credit on swap contracts	375	620	1448	5262
Gross finance costs	9640	8540	7789	35534

ii) Finance costs for the quarters ended 30 June 2015, 31 March 2015, 30 June 2014 and year ended 31 March 2015 include ₹ 921 lacs, ₹ 802 lacs, ₹ 389 lacs and ₹ 3068 lacs, respectively, towards charge on zero coupon financing of US \$ 60 million from International Finance Corporation in Jubilant Pharma Limited Singapore, a wholly owned subsidiary of the Company.

5. Exceptional items for each period presented include:

i) Amortization of debit balance in Foreign Currency Monetary Items Translation Difference Account (FCMITDA) of ₹ 790 lacs, ₹ 548 lacs, ₹ 2435 lacs and ₹ 4475 lacs for the quarters ended 30 June 2015, 31 March 2015, 30 June 2014; and year ended 31 March 2015; respectively, representing exchange difference on long-term foreign currency monetary liabilities which has been used for the purpose other than acquiring fixed assets.

ii) ₹ 6397 lacs representing write off of net book value (adjusted for net realisable value) in respect of idle assets on usability assessment recognised during the quarter and year ended 31 March 2015.

iii) The remaining amount of exceptional items, for all periods presented primarily represents foreign exchange difference for the period (excluding portion included in finance costs) and mark-to-market gain/ loss (net of related contractual recoveries) in respect of forward contracts, currency and interest rate swap contracts.

6. Previous periods figures have been reclassified to conform to the current period's classification.

7. The above unaudited results were, subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11 August 2015. The figures for the preceding quarter ended 31 March 2015, as reported in these financial results, are the balancing figures between audited figures in respect of the full financial year ended 31 March 2015 and the published year to date unaudited figures upto the end of third quarter of the financial year. Also, the figures upto the end of the third quarter of the financial year were only reviewed and not subjected to audit. The review report of the Statutory Auditors is being filed with the Bombay Stock Exchange and National Stock Exchange and is also available on the Company's website at www.jubl.com.

For Jubilant Life Sciences Limited

Place : Noida
Date : 11 August, 2015

Hari S. Bhartia
Co-Chairman & Managing Director